Humacyte, Inc. (NASDAQ:HUMA) Receives Consensus Rating of “Buy” from Brokerages

Humacyte, Inc. (NASDAQ:HUMA) has earned a consensus rating of “Buy” from the eight ratings firms that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $13.71.

Several equities research analysts recently issued reports on the company. Cantor Fitzgerald reissued an “overweight” rating and set a $13.00 price objective on shares of Humacyte in a research note on Friday, September 20th. Benchmark upped their price target on shares of Humacyte from $15.00 to $17.00 and gave the company a “buy” rating in a research report on Monday, December 23rd. BTIG Research restated a “buy” rating and issued a $10.00 target price on shares of Humacyte in a report on Friday, October 18th. Piper Sandler set a $6.00 price target on shares of Humacyte and gave the company a “neutral” rating in a research report on Friday, October 18th. Finally, D. Boral Capital restated a “buy” rating and issued a $25.00 price objective on shares of Humacyte in a research report on Friday, December 20th.

Humacyte Trading Down 1.5 %

Shares of Humacyte stock opened at $4.61 on Monday. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.10 and a quick ratio of 1.10. The firm has a market cap of $580.21 million, a PE ratio of -3.44 and a beta of 1.32. Humacyte has a 1 year low of $2.48 and a 1 year high of $9.97. The stock has a fifty day moving average price of $4.67 and a 200-day moving average price of $5.69.

Insider Buying and Selling at Humacyte

In related news, Director Brady W. Dougan sold 427,459 shares of Humacyte stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $4.34, for a total transaction of $1,855,172.06. Following the transaction, the director now directly owns 1,992,253 shares in the company, valued at approximately $8,646,378.02. The trade was a 17.67 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Laura E. Niklason sold 811,172 shares of the company’s stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $4.44, for a total value of $3,601,603.68. Following the completion of the sale, the chief executive officer now owns 2,419,712 shares of the company’s stock, valued at approximately $10,743,521.28. The trade was a 25.11 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 1,500,000 shares of company stock worth $6,606,799. Company insiders own 11.20% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. State Street Corp lifted its holdings in Humacyte by 66.1% in the 3rd quarter. State Street Corp now owns 4,764,155 shares of the company’s stock worth $25,917,000 after purchasing an additional 1,895,529 shares in the last quarter. Millennium Management LLC grew its holdings in Humacyte by 504.3% during the 2nd quarter. Millennium Management LLC now owns 1,599,307 shares of the company’s stock valued at $7,677,000 after buying an additional 1,334,641 shares in the last quarter. Renaissance Technologies LLC raised its position in shares of Humacyte by 693.0% during the second quarter. Renaissance Technologies LLC now owns 600,300 shares of the company’s stock valued at $2,881,000 after buying an additional 524,600 shares during the last quarter. Marshall Wace LLP lifted its holdings in shares of Humacyte by 3,301.5% in the second quarter. Marshall Wace LLP now owns 463,662 shares of the company’s stock worth $2,226,000 after buying an additional 450,031 shares in the last quarter. Finally, Deerfield Management Company L.P. Series C bought a new position in shares of Humacyte during the second quarter worth $1,550,000. 44.71% of the stock is currently owned by institutional investors.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.